Article discusses results of a phase II investigating rituximab and bortezomib as maintenance therapy following autologous stem cell transplant in mantle cell lymphoma.
Home / Resource Library / Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation